Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
Subscribe To Our Newsletter & Stay Updated